The biology and management of bone metastases

Critical Reviews in Oncology/Hematology

Volumn 31, Issue 1, 1999, Pages 89-96

  Plunkett, T A ^a   Rubens, R D ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; DRUG EFFECT; FRACTURE; HUMAN; MORBIDITY; PAIN; PATHOPHYSIOLOGY; REVIEW;

BONE NEOPLASMS; DISEASE MANAGEMENT; HUMANS;

EID: 0033015298     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00008-6     Document Type: Review

References (51)

1. Galasko C. The anatomy and pathways of bone metastases. Weiss L., Gilbert A. Bone Metastases. 1981;49-63 GK Hall, Boston.
2. Batson O. The role of vertebral veins in metastatic processes. Ann. Intern. Med. 16:1942;38-45.
3. Kanis J. Bone and cancer: pathophysiology and treatment of metastases. Bone. Suppl 17:1995;S101-S105.
4. Mundy G. Mechanisms of bone metastasis. Cancer. 80(Suppl 8):1997;1546-1556.
5. Vitte C., Fleisch H., Guenther H. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 137:1996;2324-2333.
6. Koutsilieris M., Rabbini S., Bennett H., Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J. Clin. Invest. 80:1987;941-948.
7. Guise T., Yin J., Taylor S., Kumagai Y., Dallas M., Boyce B., Yoneda T., Mundy G. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98:1996;1544-1549.
8. Coleman R., Rubens R. The clinical course of bone metastases in breast cancer. Br. J. Cancer. 77:1987;336-340.
9. Coleman R., Fogelman I., Rubens R. Hypercalcaemia and breast cancer - an increased humoral component in patients with liver metastases. Eur. J. Surg. Oncol. 14:1988;423-428.
10. Galasko C. The role of the orthopaedic surgeon in the treatment of skeletal metastases. Rubens R., Fogelman I. Bone Metastases. 1991;Springer-Verlag, London.
11. Hoskin P. Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv. 7:1988;69-86.
12. Tong D., Gillick L., Hendrickson F. The palliation of symptomatic osseous metastases: final results of the study by the RTOG. Cancer. 50:1982;893-899.
13. Blitzer P. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. Cancer. 55:1985;1468-1472.
14. Price P., Hoskin P., Easton D. et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother. Oncol. 6:1986;247-255.
15. Nielsen O., Bentzen S., Sandberg E., Gadeberg C., Timothy A. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother. Oncol. 47:1998;233-240.
16. Hoskin P., Ford H., Harmer C. Hemibody irradiation for metastatic bone pain. Clin. Oncol. 14:1989;268-276.
17. Robinson R., Spicer J., Preston D. et al. Treatment of metastatic bone pain with Strontium-89. Nucl. Med. Biol. 14:1987;219-222.
18. Quilty P., Kirk D., Bolger J. et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother. Oncol. 31:1994;33-40.
19. Serafini A., Houston S., Resche I. et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a double blind placebo-controlled clinical trial. J. Clin. Oncol. 16:1998;1574-1581.
20. Rodan G., Fleisch H. Bisphosphanates: mechanism of action. J. Clin. Invest. 97:1996;2692-2696.
21. Hughes D., Wright K., Uy H. et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone. Miner. Res. 10:1995;1478-1487.
22. Hughes D., MacDonald B., Russell R. et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term culture of human bone marrow. J. Clin. Invest. 83:1989;1930-1935.
23. Rogers M., Watts D., Russell R. Overview of bisphosphonates. Cancer. 80(Suppl 8):1997;1652-1660.
24. Shipman C., Rogers M., Apperley J. et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. 98:1997;665-672.
25. Body J., Bartl R., Burckhardt P. et al. Current use of bisphosphonates in oncology. J. Clin. Oncol. 16:1998;3890-3899.
26. Robertson A., Reed N., Ralston S. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J. Clin. Oncol. 13:1995;2427-2430.
27. Body J., Coleman R., Piccart M. Use of bisphosphonates in cancer patients. Cancer. Treat. Rev. 22:1996;265-287.
28. Vinholes J., Prakash Purohit O., Abbey M. et al. Relationship between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann. Oncol. 8:1997;1243-1250.
29. Patterson A., Powles T., Kanis J., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodranate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:1993;59-65.
30. van Holten-Verzantvoort A., Kroon H., Bijvoet O. et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:1993;491-498.
31. Conte P., Mauriac L., Calabresi F. et al. Delay in progression of bone metastases treated with intravenous pamidronate:results from a multicentre randomised controlled trial. J. Clin. Oncol. 14:1996;2552-2559.
32. Hultborn R., Ryden S., Gunderson S. et al. Efficacy of pamidronate on skeletal complications from breast cancer metastases. Acta Oncol. 35(Suppl 5):1996;73-74.
33. Hortobagyi G., Theriault R., Porter L. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl. J. Med. 335:1996;1785-1791.
34. Lipton A., Theriault R., Leff R., Gluck S. et al. Long term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia) infusions. Proc. ASCO. 16:1997;152a.
35. Hortobyagi G., Theriault R., Lipton A. et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:1998;2038-2044.
36. Lathinen R., Laasko M., Palva I. et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet. 340:1992;1049-1052.
37. McCloskey E., Maclennan I., Drayson M. et al. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br. J. Haematol. 100:1998;317-325.
38. Berenson J., Lichtenstein A., Porter L. et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl. J. Med. 334:1996;488-493.
39. Berenson J., Lichtenstein A., Porter L. et al. Long-term pamidronate pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. 16:1998;593-602.
40. Elomaa I., Blomqvist C., Porkka L., Lambert-Allardt C., Borgstrom G. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone. Suppl 8:1987;53-56.
41. Kanis J., Powles T., Paterson A., McCloskey E., Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 19:1996;663-667.
42. Diel I., Solomayer E.-F., Costa S. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New Engl. J. Med. 339:1998;357-363.
43. Powles T, Paterson A, Nevantaus A et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proc ASCO 1998; Abstr 468.
44. van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Lowik C., Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98:1996;698-705.
45. Sasaki A., Boyce B., Story K. et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:1995;3551-3557.
46. Biermann W., Cantor R., Fellin F. et al. An evaluation of the potential cost reduction resulting from use of clodronate in the treatment of metastatic cancer of the breast to bone. Bone. 12(Suppl 1):1991;S37-S42.
47. Hillner, B, Weeks J, Smith T, Desch C. Pamidronate in prevention of bone complications in metastatic breast cancer:a post-hoc cost-effectiveness analysis. Breast Cancer Res Treat 1998;50:Abstr 31.
48. Coleman R. Monitoring of bone metastases. Eur. J. Cancer. 34:1998;252-259.
49. Vinholes J., Coleman R., Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat. Rev. 22:1996;289-331.
50. Vinholes J., Guo C.-Y., Purohit O. et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Br. J. Cancer. 73:1996;1089-1095.
51. Lipton A., Demers L., Curley E. et al. Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer. 34:1998;2021-2026.